Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?
Reactivation of hepatitis B virus (HBV) infection is a well-recognized and potentially fatal complication in patients treated with chemotherapy for lymphoid malignancies. Although several guidelines recommend antiviral prophylaxis and/or monitoring for HBV-DNA, there is no consensus over what time period these should occur. Clinically, we have encountered delayed reactivation of HBV infections and have reported 12 cases of reactivation in patients. Among them, five patients developed HBV reactivation more than a year after they completed their chemotherapy. This means there can be a delayed HBV reactivation and prolonged monitoring of more than a year after cessation of chemotherapy may be needed. Hence, the current recommendation of stopping antiviral prophylaxis 6-12 months after the cessation of chemotherapy may not fully protect all patients from HBV reactivation. The optimal duration of follow-up needs to be determined, and until better guidelines are set, there is no choice but to keep monitoring patients for reactivation for as long as practicable.
First Department of Internal Medicine, Kansai Medical University, Japan. Electronic address: nakaya1016@yahoo.co.jp.
Aya
A
Nakaya
First Department of Internal Medicine, Kansai Medical University, Japan.
Shinya
S
Fujita
First Department of Internal Medicine, Kansai Medical University, Japan.
Atsushi
A
Satake
First Department of Internal Medicine, Kansai Medical University, Japan.
Takahisa
T
Nakanishi
First Department of Internal Medicine, Kansai Medical University, Japan.
Yoshiko
Y
Azuma
First Department of Internal Medicine, Kansai Medical University, Japan.
Yukie
Y
Tsubokura
First Department of Internal Medicine, Kansai Medical University, Japan.
Masaaki
M
Hotta
First Department of Internal Medicine, Kansai Medical University, Japan.
Hideaki
H
Yoshimura
First Department of Internal Medicine, Kansai Medical University, Japan.
Kazuyoshi
K
Ishii
First Department of Internal Medicine, Kansai Medical University, Japan.
Tomoki
T
Ito
First Department of Internal Medicine, Kansai Medical University, Japan.
Shosaku
S
Nomura
D004279:DNA, Viral / Q000032:analysis; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D008991:Monitoring, Physiologic; D017410:Practice Guidelines as Topic / Q000592:standards*; D011292:Premedication; D012008:Recurrence; D000069283:Rituximab / Q000627:therapeutic use; D013997:Time Factors; D014775:Virus Activation
D004279:DNA, Viral; D000069283:Rituximab
Carrier; Delayed reactivation; Reactivation; Resolved/occult HBV infection; Rituximab